NCT00556205View on ClinicalTrials.gov

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

Sunitinib orally once daily

DRUG

Bevacizumab

Intravenously every 14 days

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER